EA202091908A2 - COMBINATION THERAPY FOR TREATMENT OF ONCOLOGICAL DISEASE - Google Patents

COMBINATION THERAPY FOR TREATMENT OF ONCOLOGICAL DISEASE

Info

Publication number
EA202091908A2
EA202091908A2 EA202091908A EA202091908A EA202091908A2 EA 202091908 A2 EA202091908 A2 EA 202091908A2 EA 202091908 A EA202091908 A EA 202091908A EA 202091908 A EA202091908 A EA 202091908A EA 202091908 A2 EA202091908 A2 EA 202091908A2
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
combination therapy
oncological disease
oncological
disease
Prior art date
Application number
EA202091908A
Other languages
Russian (ru)
Other versions
EA202091908A3 (en
Inventor
Хайке Кайльхак
Сара К. Кнутсон
Кевин У. Кунц
Original Assignee
Эпизим, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизим, Инк. filed Critical Эпизим, Инк.
Publication of EA202091908A2 publication Critical patent/EA202091908A2/en
Publication of EA202091908A3 publication Critical patent/EA202091908A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Настоящее изобретение относится к композициям, содержащим ингибиторы метилтрансферазы EZH2 гистонов человека и одно или несколько других терапевтических средств, в частности противоопухолевых средств, таких как преднизон, а также к способам введения в рамках комбинированной терапии нуждающимся в этом субъектам с целью лечения онкологического заболевания.The present invention relates to compositions containing inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, in particular antineoplastic agents such as prednisone, as well as methods of administration in combination therapy to subjects in need thereof for the treatment of cancer.

EA202091908A 2014-05-13 2014-12-08 COMBINED THERAPY FOR TREATMENT OF CANCER EA202091908A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461992881P 2014-05-13 2014-05-13

Publications (2)

Publication Number Publication Date
EA202091908A2 true EA202091908A2 (en) 2020-12-30
EA202091908A3 EA202091908A3 (en) 2021-06-30

Family

ID=74100010

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091908A EA202091908A3 (en) 2014-05-13 2014-12-08 COMBINED THERAPY FOR TREATMENT OF CANCER

Country Status (1)

Country Link
EA (1) EA202091908A3 (en)

Also Published As

Publication number Publication date
EA202091908A3 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
EA201691079A1 (en) COMBINED THERAPY FOR THE TREATMENT OF ONCOLOGICAL DISEASE
EA201890009A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
EA201792304A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
EA201990665A1 (en) HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
MX2019010601A (en) Combination therapy for treating cancer.
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
EA201791095A1 (en) CANCER TREATMENT METHOD
EA201790195A1 (en) METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
EA201590855A1 (en) COMPOUNDS OF PYRROPOLYMIDININE AS KINAZ INHIBITORS
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201592068A1 (en) INHANSER INHIBITORS ZESTE HOMOLOGIST 2
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
EA201890567A1 (en) CANCER TREATMENT METHOD
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
CY1125150T1 (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201690039A1 (en) RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION
EA201792341A1 (en) DERIVATIVES OF PYRAZOLA SUITABLE AS INHIBITOR PROTEINS ACTIVATING 5-LIPOXYGENASE (FLAP)
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION